ADPT Adaptive Biotechnologies


Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
AirCarbon FootprintClimateConservationEmissionEnvironmentEnvironmentalIntensityLife CycleLifecycleMaterialsNatureOffsetPackagePackagingPandemicPlanetRaw MaterialsRecyclingScarcitySpillWasteWastewaterAccessBenefitsBlackCollective BargainingCommunityCultureCustomerCybersecurityData PrivacyData SecurityDeathDemographicDisabilityDiversityDiversity and InclusionEmployeeEmployee EngagementEmployee Resource GroupEngagementGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHuman ResourcesInjuriesInjuryLGBTQMinorityOpioidPay EquityPay for PerformancePay ParityPerquisitesPrivacyProduct QualityProduct SafetyRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupplier Code of ConductSupply ChainTalentTrainingUnionWomenWorkersWorkforceWorkplace SafetyAction PlanAnti-corruptionAnticorruptionAssessmentAssuranceAttorneys GeneralAuditBonusBribeBriberyChronicClassifiedClassified BoardCommitmentConflict of InterestCorporate GovernanceCorporate PurposeCorruptionDepartment ofEthicsExecutive CompensationExpertFinedFraudGoalsGovernanceIncentiveIncentivizeIndependenceIndependentInnovateInnovationInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMaterialityMissionOverseeOversightPerquisitePurposeQuality StandardR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleShareholder EngagementShareholder ProposalsSpecial MeetingStrategySupermajoritySustainabilitySustainableTargetsTaxTenureTransparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 11, 2021, Adaptive Biotechnologies Corporation (the “Company”) held its annual meeting of shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders voted on four proposals, as described below. Each of the proposals was described in detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 23, 2021. The vote totals noted below are final voting results from the Annual Meeting.

1.The Company’s shareholders elected the following three Class II director nominees, each to hold office until the 2024 annual meeting of shareholders or until his or her successor is elected and qualified, by the vote set forth below:

NomineeVotes ForVotes


Michelle Griffin95,779,97912,600,79614,450,327
Peter Neupert92,865,43215,515,34314,450,327
Leslie Trigg97,812,16010,568,61514,450,327

2.The Company’s shareholders approved, on a non-binding advisory basis, the 2020 compensation of its named executive officers as described in the proxy statement based on the following results:

Votes ForVotes AgainstAbstentionsBroker


3.The Company’s shareholders approved, on a non-binding advisory basis, a frequency of one year for future advisory votes on named executive officers’ compensation. After considering these results, we will hold a non-binding advisory vote on executive compensation on an annual basis until the next advisory vote on the frequency of non-binding votes on executive compensation.

One YearTwo YearsThree YearsAbstentionsBroker


4.The Company’s shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 by the vote set forth below:

Votes ForVotes AgainstAbstentions